라이엘 이뮤노파마(LYEL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $11.01 (+1.94%), 시가총액 $0.54B, 52주 최저~최고 $0.39 ~ $38.60.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate tha
라이엘 이뮤노파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
라이엘 이뮤노파마의 현재 주가는 $11.01 (+1.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
라이엘 이뮤노파마의 시가총액은 약 $0.54B입니다.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The com